A5021233731- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Biomarkers in Disease Mechanisms
- Cutaneous lymphoproliferative disorders research
- Biosimilars and Bioanalytical Methods
- Ureteral procedures and complications
- MRI in cancer diagnosis
- Radiation Dose and Imaging
Central Hospital of Putuo District
2012
Abstract Mosunetuzumab (Mosun) is a CD20xCD3 T‐cell engaging bispecific antibody that redirects T cells to eliminate malignant B cells. The approved step‐up dose regimen of 1/2/60/30 mg IV designed mitigate cytokine release syndrome (CRS) and maximize efficacy in early cycles. A population pharmacokinetic (popPK) model was developed from 439 patients with relapsed/refractory B‐Cell Non‐Hodgkin lymphoma receiving Mosun monotherapy, including fixed dosing (0.05–2.8 every 3 weeks (q3w)) Cycle 1...
Mosunetuzumab, a T‐cell engaging bispecific antibody targeting CD20xCD3, is approved for treating relapsed/refractory follicular lymphoma. This research supports the intravenous clinical dose regimen, summarizing exposure–response relationships safety and efficacy. A population pharmacokinetic model E max logistic regression models efficacy were developed using data from 439 patients with non‐Hodgkin lymphoma 159 lymphoma, respectively, Phase I/II study (NCT02500407). Data 0.2 to 60 mg...
To evaluate prognostic value of pentraxin3 ( PTX3 ) content combining with extravascular lung water index EVLWI in patients sepsis.A retrospective analysis complete clinical data septic admitted to Department Critical Care Medicine the First Affiliated Hospital Zhengzhou University from February 2013 2014 was conducted. These were divided into two groups, survival group and death group, according outcome on 28th day. Pulse continuous cardiac output PiCCO used record levels 1st, 2nd 3rd day...